Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets). Merger completed; transaction consideration included unregistered Lexeo common shares issued under Securities Act Section 4(a)(2) and/or Regulation D.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger completed; transaction consideration included unregistered Lexeo common shares issued under Securities Act Section 4(a)(2) and/or Regulation D
- Share issuance creates potential dilution for existing shareholders
- Contingent consideration remains tied to future achievement events, creating additional potential obligations
- Transaction outcomes depend on clinical development, regulatory approvals, liquidity, and capital resources
- Investors should review the merger agreement exhibit for share count, contingent payments, and transaction economics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.